Citadel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Citadel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$396K	Buy	75,700 +7,600	+11%	+$42.4K	﹤0.01%	9842
2025 Q4	$403K	Sell	68,100 -43,100	-39%	-$310K	﹤0.01%	9523
2025 Q3	$763K	Buy	111,200 +28,900	+35%	+$234K	﹤0.01%	8144
2025 Q2	$627K	Buy	82,300 +33,100	+67%	+$140K	﹤0.01%	8102
2025 Q1	$160K	Sell	49,200 -23,200	-32%	-$97.3K	﹤0.01%	10773
2024 Q4	$326K	Buy	72,400 +6,000	+9%	+$30.4K	﹤0.01%	9483
2024 Q3	$184K	Buy	66,400 +58,200	+710%	+$179K	﹤0.01%	10278
2024 Q2	$28K	Buy	+8,200	New	+$37.6K	﹤0.01%	12334

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's SGMT Position: Q1 2026 in Review

Citadel Advisors increased its Sagimet Biosciences (SGMT) stake by 8% in Q1 2026, buying an estimated $28.2K and bringing the position to 68,173 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10083.

Citadel Advisors first reported a position in SGMT in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.09M in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Citadel Advisors held 68,173 shares of Sagimet Biosciences worth $356K as of Q1 2026.
Citadel Advisors bought 5,054 Sagimet Biosciences shares in Q1 2026, an estimated $28.2K.
Sagimet Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10083 holding.
Citadel Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 10 quarters since.
Citadel Advisors's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.